Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
| ▸ | MARS1 | P56192 | 10/20 | 0.37 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 2/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | BHMT | Q93088 | 1/20 | 0.33 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5617582 | 0.90 | RNPEP (0.42) | RNPEPMETAP2METAP1MARS1ANPEP | |
| SCHEMBL6045793 | 0.90 | RNPEP (0.42) | RNPEPMETAP2METAP1MARS1ANPEP | |
| SCHEMBL162031 | 0.90 | RNPEP (0.42) | RNPEPMETAP2METAP1MARS1ANPEP | |
| SCHEMBL20996747 | 0.90 | RNPEP (0.42) | RNPEPMETAP2METAP1MARS1ANPEP | |
| SCHEMBL27883634 | 0.87 | RNPEP (0.37) | RNPEPMETAP2METAP1MARS1ANPEP | |
| SCHEMBL17975913 | 0.85 | RNPEP (0.38) | RNPEPMETAP2METAP1MARS1ANPEP | |
| SCHEMBL1129959 | 0.85 | RNPEP (0.38) | RNPEPMETAP2METAP1MARS1ANPEP | |
| SCHEMBL14754348 | 0.84 | RNPEP (0.41) | RNPEPMETAP2METAP1MARS1ANPEP | |
| SCHEMBL250758 | 0.84 | RNPEP (0.41) | RNPEPMETAP2METAP1MARS1ANPEP | |
| SCHEMBL1828293 | 0.84 | METAP2 (0.35) | RNPEPMETAP2METAP1MARS1ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192095-A1 | AMINO ACID AND PEPTIDE PRODRUGS OF OPIOID ANALGESICS WITH REDUCED GI SIDE-EFFECTS | SHIRE LLC (US) | 2009-07-30 | — | — | US | claimed |
| WO-2009092073-A2 | AMINO ACID AND PEPTIDE PRODRUGS OF OPIOID ANALGESICS WITH REDUCED GI SIDE-EFFECTS | SHIRE LLC (US) | 2009-07-23 | — | — | WO | claimed |
| WO-2009092071-A2 | AMINO ACID AND PEPTIDE PRO-DRUGS OF PHENOLIC ANALGESICS AND USES THEREOF | SHIRE LLC (US) | 2009-07-23 | — | — | WO | claimed |
| US-20090186832-A1 | AMINO ACID PEPTIDE PRO-DRUGS OF PHENOLIC ANALGESICS AND USES THEREOF | SHIRE LLC (US) | 2009-07-23 | — | — | US | claimed |
| US-20120270847-A1 | NOVEL CARBAMATE AMINO ACID AND PEPTIDE PRODRUGS OF OPIATES AND USES THEREOF | SHIRE LLC (US) | 2012-10-25 | — | — | US | disclosed |
| EP-2453900-A1 | NOVEL CARBAMATE AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | Shire LLC (US) | 2012-05-23 | — | — | EP | disclosed |
| WO-2011007247-A1 | NOVEL CARBAMATE AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | SHIRE LLC (US) | 2011-01-20 | — | — | WO | disclosed |
| US-20110015182-A1 | NOVEL CARBAMATE AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | SHIRE LLC | 2011-01-20 | — | — | US | disclosed |
| US-20090192095-A1 | AMINO ACID AND PEPTIDE PRODRUGS OF OPIOID ANALGESICS WITH REDUCED GI SIDE-EFFECTS | SHIRE LLC (US) | 2009-07-30 | — | — | US | disclosed |
| WO-2009092073-A2 | AMINO ACID AND PEPTIDE PRODRUGS OF OPIOID ANALGESICS WITH REDUCED GI SIDE-EFFECTS | SHIRE LLC (US) | 2009-07-23 | — | — | WO | disclosed |
| US-20090186832-A1 | AMINO ACID PEPTIDE PRO-DRUGS OF PHENOLIC ANALGESICS AND USES THEREOF | SHIRE LLC (US) | 2009-07-23 | — | — | US | disclosed |
| EP-1575900-A4 | N-METHYL AMINO ACIDS | UBIQUITOUS TECHNOLOGIES PTY LT (AU) | 2007-02-21 | — | — | EP | disclosed |
| US-20050245432-A1 | N-methyl amino acids | UBIQUITOUS TECHNOLOGIES PTY. LTD. (AU) | 2005-11-03 | — | — | US | disclosed |
| EP-1575900-A1 | N-METHYL AMINO ACIDS | UBIQUITOUS TECHNOLOGIES PTY LTD (AU) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004007427-A1 | N-METHYL AMINO ACIDS | UBIQUITOUS TECHNOLOGIES PTY LTD (AU) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245432-A1 | N-methyl amino acids | VIP, NPPA, PTMS | RNPEP 46/4885METAP2 50/4885METAP1 34/4885 |
| US-20110015182-A1 | NOVEL CARBAMATE AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | OPRL1, OPRM1, DNPEP | RNPEP 70/4885METAP2 93/4885METAP1 16/4885 |
| US-20120270847-A1 | NOVEL CARBAMATE AMINO ACID AND PEPTIDE PRODRUGS OF OPIATES AND USES THEREOF | OPRL1, OPRM1, DNPEP | RNPEP 61/4885METAP2 78/4885METAP1 14/4885 |
| US-20090186832-A1 | AMINO ACID PEPTIDE PRO-DRUGS OF PHENOLIC ANALGESICS AND USES THEREOF | DNPEP, PEPD, PREP | RNPEP 90/4885METAP2 34/4885METAP1 9/4885 |
| US-20090192095-A1 | AMINO ACID AND PEPTIDE PRODRUGS OF OPIOID ANALGESICS WITH REDUCED GI SIDE-EFFECTS | OPRL1, OGFR, OPRK1 | RNPEP 58/4885METAP2 142/4885METAP1 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.